152
VOLUME 9 NUMBER 4 • NOVEMBER 2012
REVIEW
SA JOURNAL OF DIABETES & VASCULAR DISEASE
References
1.
Hugo J, Allen L. Doctors for Tomorrow. Grahamstown: NISC, 2008. MED 610.968.
2.
The WHO–WONCA. 1995–1998. Progress report and the WHO–WONCA 1998–
2001
action plans. Making medical practice and education more relevant to
people’s need: the contribution of the family doctor. Geneva: WHO.
3.
Mc Whinney IR.
A Textbook of Family Medicine
.
Oxford University Press, 1989.
4.
Mthethwa S. Directorate Non-Communicable Diseases. Department of Health,
KwaZulu/Natal.
5.
Klisiewicz AM, Raal FJ. Sub-optimal management of type 2 diabetes mellitis. A
local audit.
J Endocrinol Metabol Diabetes S Afr
2009;
14
(1): 13–16.
6.
Chijioke A, Adamu AN, Makusidi AM. Mortality patterns among type 2 diabetes
mellitus patients in llorin, Nigeria.
J Endocrinol Metabol Diabetes S Afr
2010;
15
(2): 79–82.
7.
Aalbers J. South African patients with diabetes are under-treated for
hypercholesterolaemia.
S Afr J Diabetes Vasc Dis
2011;
8
(4): 2–3.
8.
Van derMerwe L. Pre-diabetes: A focus on the role of diabetes education in prevention
of type 2 diabetes.
J Endocrinol Metabol Diabetes S Afr
2011;
16
(1): 64–65.
9.
Distiller LA. The importance of risk factor control. A Three-Day Advanced Course
in Diabetes Care for Health Professionals 2008; 1–17.
10.
Distiller LA. Setting glycaemic targets in patients with type 2 diabetes. Where to
now?
J Endocrinol Metabol Diabetes S Afr
2009;
14
(3): 125–128.
11.
Jardine G. Obesity and dietary behavioural changes.
J Endocrinol Metabol
Diabetes S Afr
2010;
15
(2): 88–90.
12.
Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes.
Diabetes, Obes Metabol
2010;
3
(1): 45–55.
13.
Smalberger R. Obesity, the South African time bomb.
S Afr Cardiol Stroke
2008;
2
(4): 30–34.
14.
Jacob S. Cardio-metabolic risk management in type 2 diabetes.
Update
2012;
34
(3): 24.
15.
Van Rensburg G. Guidelines and consensus on foot care in diabetes.
S Afr J
Diabetes Vasc Dis
2012;
5
(1): 5–9.
16.
Van Rensburg G. Early detection of diabetic peripheral neuropathy. Clinical
benefits.
S Afr J Diabetes Vasc Dis
2012;
5
(2): 13–14.
17.
Phillips P, Evans A. The ABCS of foot care in diabetes: assessing the risk factors.
Mod Med S Afr
2010;
35
(4): 48–51.
18.
The 2012 SEMDSA guidelines for the management of type 2 diabetes.
J Endocrinol
Metabol Diabetes S Afr
2012;
17
(1):
S1–94.
19.
Phillips P. The ABC’s of diabetic care. B is for Blood pressure.
Mod Med S Afr
2008;
33
(3): 38–42.
20.
Young M. Behaviour change and motivational interviewing in the patient with
diabetes.
J Endocrinol Metabol Diabetes S Afr
2010;
15
(1): 45–47.
21.
Mhlongo SWP, Mash B.
Handbook of Family Medicine
.
Ch 5 and 6. Oxford,
2000.
22.
Distiller LA. Intensive glycaemic control and macrovascular disease. Do we have
the answer?
S Afr Cardiol Stroke
2008;
2
(3): 21–31.
23.
South African Dyslipidaemia Guideline Consensus Statement.
S Afr Med J
2012;
102
(3): 178–187.
24.
Bolliger C, van Biljon X. Successful smoking-cessation strategies for the GP.
Mod
Med S Afr
2004;
29
(9): 44–48.
25.
Certificate in Diabetes Care (CIDC). Warwick Diabetes Care Course 2006:
69–73.
26.
Gaede P, Lund-Anderson H,
et al
.
Effects of a multifactorial intervention on
mortality in type 2 diabetes.
N Eng J Med
2008;
358
: 580–591.
27.
Centre for Diabetes and Endocrinology (CDE). Advanced Course in Diabetes
cdecentr@iafrica.com
.
28.
Fehrsen S. Organisation and management principles. The quality improvement
(
QI) cycle.
Handbook of Family Medicine
.
Oxford, 2000: 268–271.
29.
Stott NCH. Primary health care. Bridging the gap between theory and practice.
Springer-Verlag, 1983: 13–20.
30.
Neighbor W. Chronic disease management. 34th Annual Advances in Family
Practice and Primary Care. 11–15 September 2006, University of Washington
School of Medicine, Department of Family Medicine.
It's the
shell that
makes
safer.
Safety-Coated
R
81
mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.
1,2,3,4,5,6,7,8,9 11,12,13,14,15,16,17,18,19,20,...52